Immunotherapy as new approach to battle senescent cells


New study have taken a CAR-T immunotherapy approach to removing senescent cells.
Identified urokinase-type plasminogen activator receptor (uPAR), as suitable target.
uPar is a cell-surface protein widely activated in senescent cells.
CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma.
These are mice that are treated with a senescence-inducing combination of drugs.
Also, it restored tissue homeostasis in mice with liver fibrosis induced chemically or by diet.
Results establish therapeutic potential of senolytic CAR T cells for senescence-associated diseases.
Researchers from Memorial Sloan Kettering Cancer Center, published in Nature.

Successful in mice, it may help treat many age-related disease in human

Mentioned in this article:

Health Organisation Memorial Sloan Kettering Cancer Center - Cancer treatment and research institution in New York City

Journal Nature

Read full article on Life Extension Advocacy Foundation (LEAF) website
More Senescent Cells information, news and resources
More Ageing Research information, news and resources